VDA-1102 is an anti-neoplastic agent that utilizes a novel mechanism of action involving selective modulation of VDAC/HK2, a molecular system that is unique to glycolysis and mitochondrial function in cancer cells and activated immune cells (such as T cells and macrophages). VDA-1102’s mechanism of action exerts multiple effects on the tumor, the tumor microenvironment, and select activated immune cells.
VDA-1102 has demonstrated significant anti-neoplastic potency in vitro and in vivo against a range of solid tumors. Therefore, VDA-1102 is being developed for parenteral administration as a systemic treatment for solid tumors.